The Effect of Transcranial Direct Stimulation on Cognitive Functions of Healthy Adults

The Effect Of Transcranial Direct Stimulation Applied To The Dorsolateral Prefrontal Cortex And Posterior Parietal Cortex İn Cognitive Function, Mood And Proprioception İn Healthy Adults

Background: Transcranial direct current stimulation(tDCS) has been used to improve cognitive functions in healthy young adults.

Purpose: To investigate the effect of TDCS application on different cortex regions on cognitive function.

Methods: Sixty individuals aged 18-30 were included in the study. The participants were randomly divided into the left dorsolateral prefrontal cortex (Left DLPFC Group)(n=20), the right posterior parietal cortex (Right PPC Group)(n=20), and the sham group (Sham Group)(n=20). tDCS was applied for 20 minutes on weekdays for 2 weeks. The participants were evaluated in terms of cognitive functions with Neuropsychometric Test Battery before and after treatment.

Study Overview

• Status: Completed
• Conditions: Healthy; Cognitive Symptom
• Intervention / Treatment: Other: Transcranial Direct Current Stimulation

• Study Type: Interventional
• Enrollment (Actual): 57
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Istanbul, Turkey, 34000
    • Damla Ören
  • Istanbul, Turkey, 34000
    • Medipol Mega Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 30 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• being 18-30 years old

Exclusion Criteria:

• alcohol and substance addiction
• previous mental illness
• having mental and cognitive problems
• a history of head trauma
• having cardiovascular disease.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: LEFT DLPFC; The anode electrode of tDCS was applied to the left DLPFC and the cathode electrode was connected to the contralateral shoulder.	Other: Transcranial Direct Current Stimulation; The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
Active Comparator: RİGHT PPC; The anode electrode of tDCS was applied to the right PPC and the cathode electrode was connected to the contralateral shoulder.	Other: Transcranial Direct Current Stimulation; The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
Sham Comparator: Sham; Placebo was applied by placing the electrodes in the right PPC and left DLPFC without applying current.	Other: Transcranial Direct Current Stimulation; The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Neuropsychiatric Test Battery	It is a test battery for getting detailed information about general cognitive status.	3 weeks
Beck Depression Scale	It measures the symptoms seen in depression such as emotional, cognitive and motivational. It includes 21 items determine a behavioral feature related to depression. Items are numbered from 0 to 3. The goal is to objectively break down the degree of symptoms. The total score of all answers is calculated as follows: 0 to 9 points: Minimally depressive symptoms 10 to 16 points: Mild depressive symptoms Between 17 and 29 points: Moderate depressive symptoms Between 30 and 63 points: Severe depressive symptoms	3 weeks

Collaborators and Investigators

• Sponsor: Medipol University
• Investigators: Study Chair: Lutfu Hanoglu, PhD, Medipol University; Principal Investigator: Miray BUDAK, PhD, Medipol University

Study record dates

Study Major Dates

• Study Start (Actual): October 10, 2019
• Primary Completion (Actual): May 10, 2020
• Study Completion (Actual): June 10, 2020

Study Registration Dates

• First Submitted: April 14, 2021
• First Submitted That Met QC Criteria: May 4, 2021
• First Posted (Actual): May 5, 2021

Study Record Updates

• Last Update Posted (Actual): May 5, 2021
• Last Update Submitted That Met QC Criteria: May 4, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Keywords: tDCS; Cognitive Function; Dorsolateral Prefrontal Cortex; Posterior Parietal Cortex
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations
• Other Study ID Numbers: tDCS on DLPFC and PPC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No